1 | A bill to be entitled |
2 | An act relating to pedigree papers; amending s. 499.003, |
3 | F.S.; clarifying that a pedigree paper may be in paper or |
4 | electronic form; revising the record requirements for |
5 | pedigree papers; amending s. 499.0121, F.S.; removing the |
6 | expiration dates of certain provisions relating to the |
7 | establishment and maintenance of prescription drug |
8 | distribution records; providing an effective date. |
9 |
|
10 | Be It Enacted by the Legislature of the State of Florida: |
11 |
|
12 | Section 1. Paragraph (b) of subsection (31) of section |
13 | 499.003, Florida Statutes, is amended to read: |
14 | 499.003 Definitions of terms used in ss. 499.001- |
15 | 499.081.--As used in ss. 499.001-499.081, the term: |
16 | (31) "Pedigree paper" means: |
17 | (b) Effective July 1, 2006, a document in a paper or |
18 | electronic form approved by the Department of Health and |
19 | containing information that records each distribution of any |
20 | given legend drug, from sale by a pharmaceutical manufacturer, |
21 | through acquisition and sale by any wholesaler or repackager, |
22 | until final sale to a pharmacy or other person administering or |
23 | dispensing the drug. The information required to be included on |
24 | a legend drug's pedigree paper must at least detail the amount |
25 | of the legend drug, its dosage form and strength, its lot |
26 | numbers, the name and address of each owner of the legend drug |
27 | and his or her signature, its shipping information, including |
28 | the name and address of each person certifying delivery or |
29 | receipt of the legend drug, and a certification that the |
30 | recipient has authenticated the pedigree papers. It must also |
31 | include the name, address, telephone number and, if available, |
32 | e-mail contact information of each wholesaler involved in the |
33 | chain of the legend drug's custody. The department shall adopt |
34 | rules and a form relating to the requirements of this paragraph |
35 | no later than 90 days after the effective date of this act. |
36 | Section 2. Paragraphs (d), (e), and (h) of subsection (6) |
37 | of section 499.0121, Florida Statutes, are amended to read: |
38 | 499.0121 Storage and handling of prescription drugs; |
39 | recordkeeping.--The department shall adopt rules to implement |
40 | this section as necessary to protect the public health, safety, |
41 | and welfare. Such rules shall include, but not be limited to, |
42 | requirements for the storage and handling of prescription drugs |
43 | and for the establishment and maintenance of prescription drug |
44 | distribution records. |
45 | (6) RECORDKEEPING.--The department shall adopt rules that |
46 | require keeping such records of prescription drugs as are |
47 | necessary for the protection of the public health. |
48 | (d)1. Each person who is engaged in the wholesale |
49 | distribution of a prescription drug, and who is not an |
50 | authorized distributor of record for the drug manufacturer's |
51 | products, must provide to each wholesale distributor of such |
52 | drug, before the sale is made to such wholesale distributor, a |
53 | written statement under oath identifying each previous sale of |
54 | the drug back to the last authorized distributor of record, the |
55 | lot number of the drug, and the sales invoice number of the |
56 | invoice evidencing the sale of the drug. The written statement |
57 | must accompany the drug to the next wholesale distributor. The |
58 | department shall adopt rules relating to the requirements of |
59 | this written statement. This paragraph does not apply to a |
60 | manufacturer unless the manufacturer is performing the |
61 | manufacturing operation of repackaging prescription drugs. |
62 | 2. Each wholesale distributor of prescription drugs must |
63 | maintain separate and distinct from other required records all |
64 | statements that are required under subparagraph 1. and paragraph |
65 | (e). |
66 | 3. Each manufacturer of a prescription drug sold in this |
67 | state must maintain at its corporate offices a current list of |
68 | authorized distributors and must make such list available to the |
69 | department upon request. |
70 | 4. Each manufacturer shall file a written list of all of |
71 | the manufacturer's authorized distributors of record with the |
72 | department. A manufacturer shall notify the department not later |
73 | than 10 days after any change to the list. The department shall |
74 | publish a list of all authorized distributors of record on its |
75 | website. |
76 | 5. For the purposes of this subsection, the term |
77 | "authorized distributors of record" means a wholesale |
78 | distributor with whom a manufacturer has established an ongoing |
79 | relationship to distribute the manufacturer's products. |
80 | Effective March 1, 2004, an ongoing relationship is deemed to |
81 | exist when a wholesale distributor, including any affiliated |
82 | group, as defined in s. 1504 of the Internal Revenue Code, of |
83 | which the wholesale distributor is a member: |
84 | a. Is listed on the manufacturer's current list of |
85 | authorized distributors of record. |
86 | b. Annually purchases not less than 90 percent of all of |
87 | its purchases of a manufacturer's prescription drug products, |
88 | based on dollar volume, directly from that manufacturer and has |
89 | total annual prescription drug sales of $100 million or more. |
90 | c. Has reported to the department pursuant to s. |
91 | 499.012(3)(g)2. that the wholesale distributor has total annual |
92 | prescription drug sales of $100 million or more, and has a |
93 | verifiable account number issued by the manufacturer authorizing |
94 | the wholesale distributor to purchase the manufacturer's drug |
95 | products directly from that manufacturer and that wholesale |
96 | distributor makes not fewer than 12 purchases of that |
97 | manufacturer's drug products directly from the manufacturer |
98 | using said verifiable account number in 12 months. The |
99 | provisions of this sub-subparagraph apply with respect to a |
100 | manufacturer that fails to file a copy of the manufacturer's |
101 | list of authorized distributors of record with the department by |
102 | July 1, 2003; that files a list of authorized distributors of |
103 | record which contains fewer than 10 wholesale distributors |
104 | permitted in this state, excluding the wholesale distributors |
105 | described in sub-subparagraph b.; or that, as a result of |
106 | changes to the list of authorized distributors of record filed |
107 | with the department, has fewer than 10 wholesale distributors |
108 | permitted in this state as authorized distributors of record, |
109 | excluding the wholesale distributors described in sub- |
110 | subparagraph b. |
111 |
|
112 | A wholesale distributor that satisfies the requirements of sub- |
113 | subparagraph b. or sub-subparagraph c. shall submit to the |
114 | department documentation substantiating its qualification |
115 | pursuant to sub-subparagraph b. or sub-subparagraph c. The |
116 | department shall add those wholesale distributors that the |
117 | department has determined have met the requirements of sub- |
118 | subparagraph b. or sub-subparagraph c. to the list of authorized |
119 | distributors of record on the department's website. |
120 | 6. This paragraph expires July 1, 2006. |
121 | (e)1. Notwithstanding paragraph (d), each person who is |
122 | engaged in the wholesale distribution of a specified drug must |
123 | provide to each wholesale distributor of such specified drug: |
124 | a. Upon any sale, a written statement that: |
125 | (I) If the establishment is not a member of an affiliated |
126 | group: "This establishment purchased the specific unit of the |
127 | specified drug directly from the manufacturer"; or |
128 | (II) If the establishment is a member of an affiliated |
129 | group: "This establishment or a member of my affiliated group |
130 | purchased the specific unit of the specified drug directly from |
131 | the manufacturer"; or |
132 | b. Before the wholesale distribution, a written statement, |
133 | under oath, that identifies each previous sale of the specific |
134 | unit of the specified drug back to the manufacturer of the |
135 | specified drug, the lot number of the specific unit of the |
136 | specified prescription drug, and the sales invoice number of the |
137 | invoice evidencing each previous sale of the specific unit of |
138 | the specified drug. The written statement identifying all sales |
139 | of such specific unit of the specified drug must accompany the |
140 | specific unit of the specified drug for each subsequent |
141 | wholesale distribution of the specific unit of the specified |
142 | drug to a wholesale distributor. |
143 |
|
144 | The department shall adopt rules to administer the requirements |
145 | of these written statements. |
146 | 2. As used in this paragraph, the term "specified drug" |
147 | means a specific prescription drug on the list of drugs adopted |
148 | by the department by rule. |
149 | 3.a. A drug may be placed on the list of specified drugs |
150 | if the department has seized or issued a stop sale notice on the |
151 | prescription drug because of the adulteration, counterfeiting, |
152 | or diversion of the prescription drug from the legal channels of |
153 | distribution for prescription drugs, or the United States Food |
154 | and Drug Administration, a manufacturer, a wholesale |
155 | distributor, a law enforcement agency, or a government agency |
156 | responsible for regulating the sale or distribution of |
157 | prescription drugs in another state has notified the department |
158 | in writing or through a website operated by one of said entities |
159 | that the prescription drug has been adulterated, counterfeited, |
160 | or diverted from the legal channels of distribution for |
161 | prescription drugs; and the prescription drug satisfies one of |
162 | the following criteria: |
163 | (I) The prescription drug is included among the top 150 |
164 | prescription drugs for which the state has incurred the highest |
165 | amount of Medicaid claims in the most recently ended state |
166 | fiscal year; |
167 | (II) The prescription drug is available for normal |
168 | prescription use in dosages or strengths that have a wholesale |
169 | cost of $200 or more; |
170 | (III) The prescription drug is used extensively for |
171 | patients with human immunodeficiency virus, acquired immune |
172 | deficiency syndrome, cancer, or other serious, life-threatening |
173 | conditions, where drug nonresponsiveness would not be considered |
174 | to be medically unusual; |
175 | (IV) The prescription drug is an injectable drug; |
176 | (V) The prescription drug is subject to a special, limited |
177 | distribution process and is not generally sold to wholesale |
178 | distributors by the manufacturer of the prescription drug; |
179 | (VI) The department has found not less than five instances |
180 | where statements required pursuant to paragraph (d) for the |
181 | prescription drug were not passed on other than because of |
182 | unintentional oversight, or have been passed on by or to a |
183 | wholesale distributor and such statements were fraudulent; or |
184 | (VII) A shipment of a prescription drug has been reported |
185 | to a law enforcement agency as having been stolen or as missing. |
186 | b. A prescription drug may be placed on the list of |
187 | specified drugs if the prescription drug satisfies any three of |
188 | the seven criteria set forth in sub-sub-subparagraphs (I)-(VII). |
189 | However, a prescription drug may not be included on the list of |
190 | specified drugs if the prescription drug is unlikely to be |
191 | counterfeited or diverted from the legal channels of |
192 | distribution for prescription drugs. |
193 | c. Before the department begins the rulemaking process to |
194 | place a drug on the list of specified drugs, except when the |
195 | department files a rule under the procedure specified in sub- |
196 | subparagraph e., the Drug Wholesaler Advisory Council created in |
197 | s. 499.01211 shall consider whether a prescription drug should |
198 | be included on or added to the list of specified drugs using the |
199 | criteria enumerated in sub-subparagraph a. or sub-subparagraph |
200 | b. and provide a written recommendation adopted by majority vote |
201 | to the secretary of the department concerning each such drug. |
202 | This paragraph does not apply to any list of prescription drugs |
203 | on which the department has begun rulemaking prior to this |
204 | paragraph becoming law. |
205 | d. When a prescription drug is added to the list of |
206 | specified drugs, the requirements of this paragraph shall be |
207 | effective as to the prescription drug beginning 60 days after |
208 | the effective date of the rule adding the prescription drug to |
209 | the list, except when the department files a rule under the |
210 | procedure specified in sub-subparagraph e. |
211 | e.(I) Notwithstanding chapter 120, if the Attorney General |
212 | or Statewide Prosecutor certifies to the secretary of the |
213 | department that a prescription drug should be added to the list |
214 | of specified drugs by emergency rule, the department may proceed |
215 | to add such drug to the list of specified drugs and the |
216 | emergency rule shall be effective for a period of 1 year from |
217 | the date on which the emergency rule is filed, if the department |
218 | begins the rulemaking process to adopt a permanent rule to place |
219 | the drug on the list of specified drugs not later than 90 days |
220 | after the date on which the emergency rule was filed. An |
221 | emergency rule adding a drug to the list of specified drugs may |
222 | not be renewed. |
223 | (II) A prescription drug may be placed on the list of |
224 | specified drugs through the procedure provided in this sub- |
225 | subparagraph when: |
226 | (A) The prescription drug satisfies any two of the |
227 | criteria specified in sub-subparagraph a. or sub-subparagraph |
228 | b.; or |
229 | (B) The prescription drug satisfies any one of the |
230 | criteria specified in sub-subparagraph a. or sub-subparagraph b. |
231 | if the prescription drug has not yet become available for |
232 | wholesale distribution or has been available for wholesale |
233 | distribution for not more than 60 days. |
234 | (III) Notwithstanding chapter 120, any emergency rule that |
235 | places a prescription drug on the list of specified drugs may be |
236 | challenged as being an invalid exercise of the delegated |
237 | legislative authority only if the department lacks any |
238 | substantial competent evidence that the prescription drug |
239 | satisfied the criteria required pursuant to sub-sub-subparagraph |
240 | (I) or sub-sub-subparagraph (II). Not later than 7 days after |
241 | any request by any person, the department shall provide such |
242 | person with the substantial competent evidence that justifies |
243 | the department's adoption of an emergency rule placing a |
244 | prescription drug on the list of specified drugs. |
245 | (IV) The department shall notify all prescription drug |
246 | wholesalers and out-of-state prescription drug wholesalers by |
247 | electronic means, facsimile, or United States mail and on the |
248 | bureau's website when any emergency rule is adopted which places |
249 | a prescription drug on the list of specified drugs. Not later |
250 | than 7 days after the department adopts an emergency rule |
251 | placing a prescription drug on the list of specified drugs, |
252 | wholesalers shall provide the department with the lot numbers |
253 | and quantities of such prescription drug which the wholesaler |
254 | owns or has in transit on the date that the department adopted |
255 | the emergency rule placing the prescription drug on the list of |
256 | specified drugs. |
257 | (V) The requirements of subparagraph 1. do not apply to |
258 | those lot numbers and quantities of a prescription drug which |
259 | are included on a report filed pursuant to sub-sub-subparagraph |
260 | (IV), and paragraph (d) shall apply to those lot numbers and |
261 | quantities of the prescription drug. In addition to the |
262 | requirements of paragraph (d), any wholesale distributor selling |
263 | a prescription drug included on a report filed pursuant to sub- |
264 | sub-subparagraph (IV) shall provide any wholesaler purchasing |
265 | the prescription drugs with a statement under oath that the |
266 | prescription drugs are among those included on a report filed |
267 | pursuant to sub-sub-subparagraph (IV) and with a copy of the |
268 | report filed by the wholesale distributor with the department |
269 | for those prescription drugs. |
270 | f. Not less than annually, the council and department |
271 | shall evaluate whether each prescription drug included on the |
272 | list of specified drugs should remain on the list. In |
273 | determining whether a prescription drug should remain on the |
274 | list of specified drugs, the council and department must |
275 | consider: |
276 | (I) The availability of generic forms of the drug. |
277 | (II) Changes in the price of the drug since the |
278 | prescription drug was placed on the list. |
279 | (III) The current status of the drug that caused the |
280 | department to place the prescription drug on the list of |
281 | specified drugs. |
282 |
|
283 | The council shall provide a written recommendation adopted by |
284 | majority vote to the secretary of the department concerning each |
285 | drug that the council recommends be removed from the list of |
286 | specified drugs. |
287 | 4. This paragraph does not apply to a manufacturer; |
288 | however, a repackager must comply with this paragraph. |
289 | 5. This paragraph expires July 1, 2006. |
290 | (h)1. This paragraph applies only to an affiliated group, |
291 | as defined by s. 1504 of the Internal Revenue Code of 1986, as |
292 | amended, which is composed of chain drug entities, including at |
293 | least 50 retail pharmacies, warehouses, or repackagers, which |
294 | are members of the same affiliated group, if the affiliated |
295 | group: |
296 | a. Discloses to the department the names of all its |
297 | members; and |
298 | b. Agrees in writing to provide records on prescription |
299 | drug purchases by members of the affiliated group not later than |
300 | 48 hours after the department requests such records, regardless |
301 | of the location where the records are stored. |
302 | 2. Each warehouse within the affiliated group must comply |
303 | with all applicable federal and state drug wholesale permit |
304 | requirements and must purchase, receive, hold, and distribute |
305 | prescription drugs only to a retail pharmacy or warehouse within |
306 | the affiliated group. Such a warehouse is exempt from providing |
307 | a pedigree paper in accordance with paragraphs (d) and (e) to |
308 | its affiliated group member warehouse, provided that: |
309 | a. Any affiliated group member that purchases or receives |
310 | a prescription drug from outside the affiliated group must |
311 | receive a pedigree paper if the prescription drug is distributed |
312 | in or into this state and a pedigree paper is required under |
313 | this section and must authenticate the documentation as required |
314 | in subsection (4), regardless of whether the affiliated group |
315 | member is directly subject to regulation under this chapter; and |
316 | b. The affiliated group makes available to the department |
317 | on request all records related to the purchase or acquisition of |
318 | prescription drugs by members of the affiliated group, |
319 | regardless of the location where the records are stored, if the |
320 | prescription drugs were distributed in or into this state. |
321 | 3. If a repackager repackages prescription drugs solely |
322 | for distribution to its affiliated group members for the |
323 | exclusive distribution to and among retail pharmacies that are |
324 | members of the affiliated group to which the repackager is a |
325 | member: |
326 | a. The repackager must: |
327 | (I) In lieu of the written statement required by paragraph |
328 | (d) or paragraph (e), for all repackaged prescription drugs |
329 | distributed in or into this state, state in writing under oath |
330 | with each distribution of a repackaged prescription drug to an |
331 | affiliated group member warehouse or repackager: "All repackaged |
332 | prescription drugs are purchased by the affiliated group |
333 | directly from the manufacturer or from a prescription drug |
334 | wholesaler that purchased the prescription drugs directly from |
335 | the manufacturer."; |
336 | (II) Purchase all prescription drugs it repackages: |
337 | (A) Directly from the manufacturer; or |
338 | (B) From a prescription drug wholesaler that purchased the |
339 | prescription drugs directly from the manufacturer; and |
340 | (III) Maintain records in accordance with this section to |
341 | document that it purchased the prescription drugs directly from |
342 | the manufacturer or that its prescription drug wholesale |
343 | supplier purchased the prescription drugs directly from the |
344 | manufacturer. |
345 | b. All members of the affiliated group must provide to |
346 | agents of the department on request records of purchases by all |
347 | members of the affiliated group of prescription drugs that have |
348 | been repackaged, regardless of the location where the records |
349 | are stored or where the repackager is located. |
350 | 4. This paragraph expires July 1, 2006. |
351 | Section 3. This act shall take effect July 1, 2005. |